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CASE PRESENTATION
A  22-year-old woman was referred to the University Hospital St. 
Radboud eight years ago because of general fatigue, arthralgias, myalgias, 
facial rash, and a fever (38.1°C). H er general physician had prescribed 
salicylates and later nonsteroidal anti-inflammatory drugs, which partially 
relieved the symptoms. Several years before, systemic lupus erythematosus 
(SLE) had been diagnosed in one of her sisters who had had similar 
complaints.
Physical examination of this healthy-looking, white female revealed a 
typical butterfly rash on the face but no further skin abnormalities. Her 
blood pressure was 140/70 mm Hg supine and standing, and the pulse rate 
was 76 beats/min and regular. She had no signs of anemia or edema. Oral 
and genital ulcers were absent as was lymphadenopathy. None of the joints 
showed signs of synovial swelling. Auscultation did not reveal a pleural or 
a pericardial rub but did disclose a systolic murmur, grade II/VI, at the left 
fourth intercostal space and the apex. These findings suggested mitral 
valve insufficiency, which was confirmed on echocardiography. Further 
physical examination was unremarkable.
Laboratory examination revealed a sedimentation rate of 106 mm/hr; 
urea, 5.6 mmol/liter; creatinine, 91 ju,mol/liter (1.0 mg/dl); and serum 
albumin, 29 g/litei\ A  24-hour urine collection contained 1.29 g of protein. 
The urinary sediment contained 5-10 polymorphic erythrocytes/high- 
powered field and numerous hyaline and red blood cell casts. The 
hemoglobin was 6.1 mmol/liter; leukocytes, 3.0 X 10y/liter; and thrombo­
cytes, 222 X 109/liter. The LDH value was elevated to 372 U/liter. Liver 
function tests all were normal. An antiglobulin test was strongly positive, 
both with an anti-IgG and an anti-complement antiserum. Serologic 
examination showed a strongly positive homogenous ANA, with a positive 
Ctithidia luciliae test indicating the presence of anti-dsDNA antibodies. 
The Farr a jsay was strongly positive, with 5000 U/mL The C3 and C4 levels
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were decreased to 559 and 99 mg/liter, respectively (normal values for C3: 
750-1250 mg/liter; C4: 180-400 mg/liter). The immunoblot on nuclear 
extracts was diffusely positive but did not disclose specific bands. Tests for 
ANCA, rheumatoid factor, anti-cardiolipin, and cryoglobulins all were 
negative. A chest radiograph and renal ultrasound examination did not 
disclose any abnormalities. A percutaneous renal biopsy had to be 
postponed because of a prolonged bleeding time due to the nonsteroidal 
drugs. To relieve her arthralgias, prednisone (25 mg/day) was prescribed, 
Two weeks later a renal biopsy was performed under ultrasound guidance. 
The specimen contained 34 glomeruli, of which 40% showed capillary loop 
necrosis with fibrin deposits. Cellular crescents were present in some 
glomeruli, Endocapillary proliferation with influx of granulocytes and 
mononuclear cells was seen in 80% of the glomeruli. The interstitium 
contained a scarce, focal mononuclear cell infiltrate. Immunofluorescent 
examination revealed coarse granular deposits of IgG (2+), IgM (3+), 
IgA (1+), Clq (4+), and C3 (4+) along the glomerular capillary walls and 
to a lesser extent in the mesangium. Based on these findings, the biopsy 
was classified as lupus nephritis WHO class IV.B with an activity index of 
IS and a chronicity index of 1.
After discussing the therapeutic options, the patient selected treatment 
with azathioprine and prednisone over cyclophosphamide and prednisone 
because of the lower risk of infertility with the former regimen, Therefore, 
the prednisone dose was raised to 60 mg/day, azathioprine was started at 
a daily dose of 125 mg (2 mg/kg), and ranitidine was added prophylactic 
cally. During this treatment, her complaints disappeared completely, the 
sedimentation rate fell from 106 to 30 mm/hr, and the serum creatinine 
decreased from 96 to 65 ¿¿mol/liter (1.1-0.7 mg/dl). The urinary protein 
excretion initially rose to 7.1 g/24 hr maximally, but thereafter decreased 
gradually to 0.8 g/24 hr, although it never became negative. Concomi­
tantly, the serum albumin rose from 29 to 41 g/liter. Hematologic 
parameters improved and became normal. The serologic immunologic 
parameters also reflected the salutary effect of the treatment: the Farr titer 
dropped to 140 U/ml (Fig. 1), and the C3 (but not the C4) level became 
normal. The azathioprine dose was kept constant; the prednisone dose was 
tapered every 4 weeks by 10 mg/day until a dose of 30 mg/day was reached. 
Thereafter, the dose was tapered every 4 weeks by 5 mg/day to a 
maintenance dose of 10 mg/day, which was reached eight months after her 
initial presentation. The course of the disease was unremarkable for five 
months, until the urinary protein excretion again rose, from 2.0 to 7.4 g/24 
hr, with a parallel decrease of her serum albumin from 44 to 33 g/liter. The 
Farr assay, which had been negative, became positive again at 12 months 
(see Fig. 1), and C3 decreased from 851 to 581 mg/liter. Clinically, she had 
no signs of disease activity.
We discussed with the patient the option of starting intravenous 
cyclophosphamide pulse therapy, but her fear of infertility prevented her 
approval. The oral prednisone dose therefore was increased to 30 mg/day, 
and she received three intravenous pulses of 1 g of methylprednisolone on 
three consecutive days; the azathioprine dose remained unchanged. With 
the new regimen, the proteinuria again fell to 2 g/24 hr, serum albumin 
rose to 38 g/liter, and the Farr assay became negative again. The 
prednisone dose was tapered as before. Within 12 months, the proteinuria 
had again increased, reaching nephrotic-range values, with a gradual 
decrease of the serum albumin level to 28 g/liter. Renal function deteri­
orated; the serum creatinine rose from 66 to 90 ¿¿mol/liter (0.7-1.0 mg/dl). 
The hemolytic anemia worsened, resulting in a hemoglobulin value of 5,8 
mmol/liter. However, the white blood cell and platelet counts rem ained  
normal. As depicted in Fig. 1, the Farr assay again became positive at 23 
months. Treatment with cyclophosphamide still was not acceptable to the
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Fig. 1. Profile of the anti-dsDNA titers over time of the presented patient 
as measured in the Farr assay (expressed as U/ml). Roman numerals 
indicate onset (I) or renal exacerbations (II, III, IV),
patient, so the oral prednisone dose was raised from 10 mg/day to 60 
mg/day. Furosemide was prescribed for her edema, After this round of 
intensification of treatment, the anti-dsDNA levels became negative, and 
the C3 and C4 values returned to normal. The proteinuria responded only 
partially (from 8 to 4 g/24 hr), although the serum albumin levels rose to 
34 g/Iiter. By 34 months after presentation (prednisone dose, 10 mg; 
azathioprine dose, 125 mg), the serologic quiescence had ended; Farr 
titers became positive again (100 U/ml). This development, together with 
an increase in proteinuria and a decrease in serum albumin, led to the 
decision to discontinue the azathioprine and to start monthly intravenous 
pulses of cyclophosphamide. At months 37 and 38, she received 1 g of 
cyclophosphamide together with hydration, ondansetron, and MESNA 
(2-mcrcapto-ethane-suIfonatc). Except for nausea after 48 hours, she 
tolerated this treatment well. The next dose of cyclophosphamide had to 
be postponed four weeks becausc of leukopenia. During that time, her 
renal condition deteriorated; the serum creatinine rose to 161 jumol/liter 
(1.8 mg/di), the urinary protein excretion increased, and the serum 
albumin decreased further to 22 g/litcr, ITer blood pressure rose to 
170/110 mm Hg, for which she was given atenolol Two weeks after the 
third cyclophosphamidc infusion, she was admitted to the hospital because 
her renal function had deteriorated further (serum creatinine, 259 ju,mol/ 
liter). Also, an increase in dsDNA titers indicated that serologically the 
disease activity had increased (Fig. 1).
In an ultimate attempt to control the disease, the oral prednisone dose 
was increased again to 60 mg/day, azathioprine therapy was reinstituted, 
and plasmapheresis was started every other day for one week and 
thereafter thrice weekly for two weeks. Blood pressure control was 
improved by adding nifedipine and increasing the dose of furosemide. This 
regimen led to a stabilization of renal function, with a serum creatinine of 
about 300 ¿imol/liter (3.4 mg/dl); a rapid decline of anti-dsDNA antibody 
titers; and a normalization of serum albumin despite proteinuria of 8 g/24 
hr. The prednisone dose was tapered as described. Beginning at 46 
months, her renal function gradually deteriorated further, resulting in a 
creatinine level of 620 /¿mol/liter (7.2 mg/dl) (51 months post presenta­
tion) despite adequate blood pressure control, immunosuppressive main­
tenance therapy, and serologic disease quiescence. Standard measures 
were taken (protein restriction, oral phosphate binders, 1 ct-hydroxy - 
vitamin D3, erythropoietin substitution) to control the manifestations of 
the progressive renal insufficiency. During extensive discussion, it was 
decided not to increase the immunosuppression and to taper the azathio­
prine and prednisone, thus accepting eventual progression to end-stage 
renal disease and opting for a renal transplant from a living-related donor.
Three months later, hemodialysis became necessary to control her 
azotemia, In the meantime, preparations for the transplantation proce­
dure had been started. After blood group and HLA typing, her mother 
offered a kidney. After a third-party blood transfusion and repeatedly 
negative cross-matching thereafter, the renal transplant was performed
three months after hemodialysis had been started. The graft functioned 
immediately, and the postoperative course was uneventful. Immunosup­
pression consisted of cyclosporine A  and prednisone. The patient was 
discharged on the 8th postoperative day in excellent condition; her serum 
creatinine was 130 /xmol/Iiter (1.5 mg/dl). Three months later, a percuta­
neous transplant biopsy was performed because of a rise of the serum 
creatinine (to 168 /¿mol/liter; 1.8 mg/dl), which could not be attributed to 
post-renal obstruction. This biopsy showed focally circumscribed areas of 
mononuclear cell infiltrates and edema in the interstitium. Mononuclear 
cells occasionally were present in the tubules. No glomerular abnormali­
ties were apparent. According to the Banff classification [1] these findings 
were classified as “borderline interstitial rejection.” There were no signs of 
cyclosporine A nephrotoxicity. The patient was treated with intravenous 
infusions of 1 g methyiprednisolone on three consecutive days. The serum 
creatinine gradually decreased to 143 ¿¿mol/liter (1.6 mg/dl). Over the past 
four years, the serum creatinine has gradually risen again to its current 
value of 165 /xmol/liter (1.8 mg/dl), but this increase paralleled her 
increase in body weight from 46 kg at transplantation to 70 kg at present. 
She currently is in excellent condition and has a full-time job. The urine 
contains no protein. Her blood pressure is 130/84 mm Hg; she takes 50 mg 
of atenolol daily. Her SLE has remained silent both clinically and 
serologically since end-stage renal failure developed four years ago.
DISCUSSION
Dr. Jo H. M, B e r d e n  (Professor o f Nephrology; Division o f 
Nephrology, University Hospital St. Radboud, Nijmegen, The Neth­
erlands): This patient illustrates the severe renal manifestations 
complicating systemic lupus erythematosus. Like SLE itself, renal 
manifestations of the disease are highly variable in their clinical 
presentation, ranging from mild proteinuria to rapidly progressive 
glomerulonephritis causing renal insufficiency within weeks [2]. 
This clinical variability is in keeping with the broad spectrum of 
histologic abnormalities present in renal biopsy specimens from 
these patients. The histologic findings in lupus nephritis are 
categorized in six groups according to a recently modified World 
Health Organization (WHO) classification (Table 1) [3]. A recent 
Nephrology Forum specifically addressed the relation between 
pathologic abnormalities and clinical symptoms [4], Using the 
case presented, I plan to focus on three other major aspects of 
SLE: (2) new insights into the pathophysiology of lupus nephritis, 
(2) treatment options in lupus nephritis, and (J) renal replace­
ment therapy in SLE.
A central feature of all renal biopsies from patients with lupus 
nephritis is the presence on immunofluorescence examination of 
immunoglobulin and complement deposits present either in the 
mesangium (WHO class II) or in the mesangium and the capillary 
loops (WHO class III, IV, or V) [3]. For many years, these 
deposits were thought to be secondary to the deposition in the 
glomerulus of DNA/anti-DNA immune complexes, because in 
SLE anti-dsDNA antibodies are found in the circulation [5], onset 
or flares of renal manifestations often are preceded by a rise in 
titer of these anti-dsDNA antibodies [6] (Fig, 1), and anti-dsDNA 
antibodies can be eluted from glomeruli in lupus nephritis [7]. 
Twenty-five years ago, this concept even led Koffler et al to 
propose SLE, and more particularly lupus nephritis, as the 
prototype of an immune-complex disease [8], Several crucial 
pieces of evidence are lacking to support this central role for 
DNA/anti-DNA complexes, however. Free DNA is not present in 
the circulation [9,10], the presence of DNA/anti-DNA complexes 
in SLE is highly questionable [11], and glomerular localization is 
rarely observed in experimental animals after intravenous injec­
tion of artificially prepared DNA/anti-DNA complexes [9]. There­
fore, alternative hypotheses have been developed.
The generation of monoclonal anti-DNA antibodies led to the
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Table 1. World Health Organization morphologic classification of lupus
nephritis (1995 revised version)1
Class Description
I
II
III
IV
v b
VI
Normal glomeruli 
A Nil (by all techniques)
B Normal by light microscopy, but deposits seen by electron or 
immunofluorescence microscopy 
Pure mesangial alterations (mesangiopathy)
A Mesangial widening an 0/or mild hypercellularity (+)
B Moderate hypercellularity ( + + )
Focal segmental glomerulonephritis (associated with mild or 
moderate mesangial alterations)
A Active necrotizing lesions 
B Active and sclerosing lesions 
C Sclerosing lesions
Diffuse glomerulonephritis (severe mesangial, endocapillary, or 
mesangiocapillary proliferation and/or extensive 
subendothelial deposits. Mesangial deposits are present 
invariably and subepilhelial deposits often, and can be 
numerous).
A Without segmental lesions 
B With active necrotizing lesions 
C With active and sclerosing lesions 
D With sclerosing lesions 
Diffuse membranous glomerulonephritis 
A Pure membranous glomerulonephritis 
B Associated with lesions of Category II (a or b)
Advanced sclerosing glomerulonephritis
“ From Ref. 3.
b In the previous version of this classification, membranous glomerulo­
nephritis accompanied by proliferative lesions in the capillary loops was 
classified as V.C/V.D. In the modified version, these forms are categorized 
in class IV.
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Fig. 2. Composition of nucleosome. The ccntral part of the nucleosome is 
formed by the histone octamer, consisting of two pairs of the H2A-H2B 
dimer and one H3-H4 tetramer. Around this octamer 145 bp of DNA arc 
wound in two superhelical turns. Histone HI interacts with the octamer/ 
DNA complex and bridges, together with stretches of linker DNA, 
adjacent nucleosomes. Note that the positively charged N-terminal regions 
of the core histones are located at the outside of the nucleosome. 
(Reproduced with permission from Scientific American. International 
Edition, October 1992, from the article “Histones as regulators of genes” 
by M. Grunstein, 40-47,)
discovery that some of these monoclonals could react with non- 
DNA antigens [12], including intrinsic glomerular basement mem­
brane (GBM) constituents like heparan sulfate [13] and laminin 
[14]. These observations suggested that anti-DNA antibodies 
could directly bind to the GBM [9, 15]. Subsequently, however, it 
was demonstrated that hislone/DNA (nucleosome) complexes 
mediate the binding of these antibodies to cell surfaces [16], to 
heparan sulfate [17], to laminin [18], and to endothelial and 
mesangial cells [19]. The hypothesis then arose that the binding of 
anti-DNA antibodies to the GBM in vivo was not direct, but 
indirect, mediated by nucleosomes [20]. According to this con­
cept, the cationic histone part of the nucleosome is responsible for 
the binding to heparan sulfate and to other anionic determinants 
in the GBM. This concept was proven experimentally by renal 
perfusion in vivo in rats of monoclonal anti-nuclear (anti-DNA 
and anti-nucleosome) antibodies complexed to nucleosomes, 
which indeed led to GBM binding, in contrast to lack of GBM 
binding when non-compJexed antibodies were utilized [21], How­
ever, nucleosomes not only appeared to be important for the 
evolution of tissue lesions and glomerulonephritis in particular, 
but also for the induction of the autoimmune response in SLE. 
Strong evidence indicates that the autoimmune response in SLE is 
(auto)antigen driven and T-cell dependent [22-24]. This conclu­
sion is based cn the following observations regarding anti-dsDNA 
antibodies: (7) they are somatically mutated, (2) they show a 
restricted ratlier than a random expression of VH and VL gene 
products, ( 3 different individuals and different species share 
common idiotypes, (4) they show a class switch to IgG and 
predominantly to the T-cell-dependent IgG2a/2b isotypes, and (5)
it appears that CD44 T-helper cells are important for their 
formation [24]. However, it is difficult to understand how DNA 
can induce an autoimmune response, because the T-cell receptor 
does not recognize oligonucleotides or naked DNA, but only 
processed peptides presented in the groove of the MHC class-II 
molecule on antigen-presenting cells. Indeed, numerous reports 
have shown that naked DNA itself is very poorly immunogenic 
[reviewed in Ref. 24]. A major breakthrough was achieved when 
it was found that the tolerance for dsDNA could be broken by 
immunization of DNA complexed to DNA-binding proteins like 
histones [reviewed in Ref. 25]. Thus the association with histones 
appears to be critical for the formation of anti-dsDNA antibodies. 
These observations provided the first indication that nucleosomes 
are important as triggering autoantigens in SLE [23, 26, 27].
New insights into the pathogenesis of lupus nephritis
Nucleosomes. Before addressing the relevance of nucleosomes 
both for the induction and the effector phase in SLE, I want to 
briefly review the structure of nucleosomes. The nucleosome, the 
basic structure of chromatin, has an important function in the 
compaction of DNA in the nucleus. It consists of pairs of the 4 
core histones—H2A, H2B, H3, and H4—forming the histone- 
octamer around which 145 bp of DNA are wound twice (Fig. 2). 
Histone HI anchors these DNA loops. Neighboring nucleosomes 
are connected with histone-free linker DNA. This architecture is 
responsible for the characteristic appearance of chromatin in 
electron microscopy as “beads-on-a-string.” Each of the 4 core 
histones is a single polypeptide chain with a molecular weight 
between 11 and 15 kD. Basic residues, which are clustered at the
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N-terminal regions of the core histones and therefore located at 
the outside of the nucleosome, create regions with a strong 
positive charge (Fig, 2). The positive charges on the cylindrical 
surface of the histone octamer are partly involved in DNA 
binding. But these regions of positive charges within the nucleo­
some also are important for binding to anionic moieties like 
heparan sulfate in the GBM, as we will discuss later.
As r said, naked DNA is not present in the circulation [9], but 
in 1990 Rumore and Steinman showed that DNA does circulate in 
the form of (oligo-) nucleosomes [28]. The presence of DNA in 
this particular form suggests that apoptosis is the source for the 
generation of these nucleosomes, Apoptosis, a process of pro­
grammed cell death, leads to a non-phlogistic removal of “un­
wanted” cells. In contrast to accidental ceil death by necrosis, 
apoptosis can yield nucleosomes, because it starts with an inter- 
nucleosomal cleavage of chromatin [29]. This nucleosomal mate­
rial together with spliceosomes (snRNP/Sm) is clustered in the 
so-called “apoptotic bodies,” which appear at the surface of the 
cell during apoptosis. Normally, apoptotic cells are phagocytosed 
rapidly both by macrophages and by neighboring parenchymal 
cells. This phagocytosis efficiently prevents the release of phlogis­
tic cell constituents into the micro-environment [30], If apoptosis 
or phagocytosis is disturbed, however, or if apoptosis occurs in the 
circulation, nucleosomes can be released systemically. Under 
in-vitro conditions in which effective phagocytosis is absent, the 
amount of nucleosomes released strongly correlates with the 
degree of apoptosis [31]. Apoptosis of lymphocytes can be in­
duced by several mechanisms, including T-cell receptor/CD3 
activation or binding of the Fas receptor to its ligand [32]. This 
Fas receptor, belonging to the TNF receptor superfamily, is not 
expressed in the spontaneous lupus model, the MRL/lpr mouse 
[33]. This observation for the first time linked disturbed apoptosis 
to SLE. Studies later reported that the defective expression of the 
Fas ligand in the gld mouse had the same consequences, namely, 
lymphoproliferation and systemic autoimmunity [34, 35], Correc­
tion of the defective expression in both models by transgenic 
techniques prevented the development of autoimmunity [36], 
Overexpression of bcl-2, a physiologic inhibitor of apoptosis, also 
leads to autoimmune features. It reduces the elimination of 
autoreactive B-cells [37], induces the formation of anti-nucleo- 
some antibodies, and leads to the development of immune- 
complex glomerulonephritis [38]. In human SLE, the expression 
of the Fas system is normal, but the increased concentrations of 
soluble Fas (which inhibits apoptosis) reported by some [39] but 
not all [40, 41] investigators, the increased expression of bcl-2 in 
T-cells in lupus patients [42], and the increased rate of apoptosis 
in vitro [31] point to abnormalities of apoptosis also.
These disturbances in apoptosis can have two major conse­
quences. First, they can lead to the persistence of autoreactive 
T-cells [43], since apoptosis is the major mechanism for shaping 
the T-cell repertoire in the thymus [32], Second, they might lead 
to quantitative and qualitative changes in the release of nucleo­
somes. This increased release of nucleosomes might be further 
augmented by defects in phagocytosis of apoptotic cells or by 
impairment of C-reactive protein-mediated clearance of nucleo­
somes [44-46]. Both processes are disturbed in SLE. Further­
more, abnormalities in apoptosis can produce structural changes 
in released nucleosomes, via oxygen-free-radical-induced protein 
modification or fragmentation [47, 48]. This effect might create 
novel epitopes within the nucleosome that induce activation of
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Fig. 3. Profile of anti-dsDNA, anti-C lq, and nucleosome-specific anti­
bodies measured during the last renal exacerbation (episode IV in Fig. 1) 
of the patient. Results are expressed as U/ml for the Farr assay and as 
titers for the two other autoantibody specificities. For the latter, the titers 
are the reciprocals of the dilutions that give an absorption of 1.0 at 450 nin 
in the ELISA.
non-tolerant T-helper cells. The causative relationship between 
apoptosis and autoantibody formation was demonstrated by the 
observation that lupus-derived, nucleosome-specific autoantibod­
ies bind to nucleosomes either present in the apoptotic bodies [47] 
or released from apoptotic cells [49], In summary, it seems that in 
genetically susceptible individuals, disturbances in apoptosis can 
contribute to the development of SLE.
Nucleosomes are probably the major autoantigens that drive 
the autoimmune response in SLE. First, Bell and coworkers 
showed that nucleosomes can act as polyclonal B-ceil activators 
[50]. More important since SLE is an antigen-driven disease, 
nucleosomes, in contrast to dsDNA or histones, can stimulate 
004"*" T-helper cells in murine lupus [51]. The same authors also 
observed that these nucleosome-specific T-helper cells could 
induce the production of anti-dsDNA and anti-histone antibodies 
by syngeneic B-cells. Mamula recently suggested that this epitope 
spreading is explained by the presentation to T-cells of previously 
cryptic epitopes unmasked during processing by antigen-present­
ing cells [52]. Second, the formation of nucleosome-specific anti­
bodies, that is, antibodies that react exclusively with the nucleo­
some, but not with its constituents DNA or histones, is reported 
with increasing frequency in SLE [reviewed in Ref. 53] and occurs 
in as many as 80% of lupus patients [26, 54]. In our patient, we 
retrospectively measured the anti-nucleosome titer in plasma 
samples set aside during her last relapse (episode IV in Fig. 1). As 
Figure 3 illustrates, an increase in nucleosome-specific antibodies 
that mimicked the course of the anti-dsDNA titer accompanied 
this last renal flare. Unfortunately no blood samples were avail­
able from the initial phase of her disease. Studies show that the 
formation of these nucleosome-specific antibodies precedes the 
formation of antibodies with other anti-nuclear specificity, for 
example, anti-dsDNA and anti-histone [26, 55, 56]. At present not 
enough data exist to relate nucleosome-specific antibodies to 
certain SLE disease manifestations such as lupus nephritis. Until 
now either a positive association [26, 49] or none at all [57] has
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been described. Third, a number of indications suggest that the 
incidence of nucleosome-specific antibodies in SLE is higher than 
thought because some anti-DNA antibodies are, in fact, nucleo­
some-specific antibodies. Anti-nudeosome antibodies complexed 
to nucleosomal antigens can display anti-DNA reactivity in the 
dsDNA-ELISA, but more important, also in the Farr assay [21], 
which is regarded as the “gold standard” for the detection of 
anti-DNA antibodies [58]. This DNA reactivity is caused by the 
cationic histone within the nucleosome, complexed to the auto- 
antibody, Removal of the bound nucleosomes abrogated this 
DNA reactivity, but the nucleosome reactivity remained. This 
phenomenon was first observed for monoclonal antibodies, but 
evidence now suggests that it also applies to polyclonal antibodies 
from patients with lupus. Exposure of Farr-positive blood samples 
from SLE patients to high-salt conditions and DNAse reduced 
Farr reactivity by 70%; reactivity towards other autoantigens 
(nucleosomes/SS-A) or control antigens (EBV) remained unal­
tered [59]. Another indication that anti-DNA reactivity might be 
due to nucleosome-specific antibodies comes from the observa­
tion that monoclonals with a high affinity for dsDNA bind even 
better to nucleosomes than to dsDNA, as revealed by the mea­
surement of equilibrium affinity constants in a sensitive system 
[60]. Taken together, these data indicate the importance of the 
nucleosome as a dominant driving autoantigen in lupus, and 
suggest that the loss of tolerance for nucleosomes is an initial key 
event in this disease.
Besides their role as autoantigens, nucleosomes also participate 
in the evolution of tissue lesions, especially glomerulonephritis. 
The binding of antinuclear antibodies to nucleosomes (either in 
the circulation or locally) can be a potential phlogistic threat for 
the glomerulus. When we analyzed the “cross-reactivity” of anti- 
DNA antibodies with heparan sulfate, we discovered that this 
binding to heparan sulfate was not a direct binding but was 
mediated by nucleosomes [17]. Because of the pivotal role of 
heparan sulfate for the charge-dependent permeability of the 
GBM [61], and the fact that neutralization of, or antibody binding 
to, heparan sulfate leads to massive albuminuria [62], this auto- 
antibody binding to heparan sulfate might be a critical pathophys­
iologic event. Thus the important question arose: Do histones and 
DNA or, physiologically more relevant, nucleosomes mediate the 
binding to heparan sulfate in the GBM in vivo? Indeed, we and 
others have proved this to be the case both for histones/DNA [63, 
64] and for nucleosomes [21], as analyzed in an in-vivo renal 
perfusion system in the rat. Perfusion of non-complexed, purified 
antinuclear autoantibodies did not lead to glomerular binding, 
thereby refuting the previously suggested possibility of “direct” 
binding to GBM constituents [9, 15, 65], Removal of heparan 
sulfate from the GBM (by prior perfusion with heparan sulfate- 
degrading enzjmes) considerably reduced GBM binding of nu­
cleosome-complexed autoantibodies but did not completely pre­
vent it [21]. Recent findings have indicated that collagen IV also 
can act as a ligand for such nucleosome-complexed autoantibodies 
[66, 67]. It is interesting that the presence of nucleosome- 
complexed autoantibodies showed a high correlation with the 
occurrence of lupus nephritis in both experimental lupus in mice 
[68] and patients [69]. Because heparin has strong structural 
similarities with heparan sulfate, we evaluated whether heparin 
could inhibit the binding of nucleosome-complexed autoantibod­
ies to the GBM. In the in-vivo renal perfusion system, heparin 
completely prevented this binding. Moreover, long-term adminis­
tration of heparin and non-coagulant heparin analogues in MRL/ 
Ipr mice prevented immune-complex deposition in the glomerular 
capillary loops, reduced the severity of the glomerulonephritis, 
and prevented albuminuria [70],
What is the evidence that this nucleosome-mediated binding 
occurs in lupus nephritis? (/) Analysis of GBM heparan sulfate 
staining with immunofluorescence, using GBM-heparan sulfate* 
specific monoclonal antibodies [62, 71], revealed a strong reduc­
tion of GBM-heparan sulfate staining both in human [72] and in 
murine lupus nephritis [73], This lack of staining was not due to a 
reduction of the amount of heparan sulfate, but to masking of the
heparan sulfate by nucleosome-containmg immune complexes
[73], (2) Using nucleosome-specific monoclonal antibodies as a 
probe, we recently identified for the first time nucleosomes in 
glomerular immune deposits in 45% of the biopsy specimens from 
patients with diffuse proliferative (WHO class IV) lupus nephritis
[74], The presence of histones in 100% of these biopsies con­
firmed previous reports [75]. The difference between the fre­
quency of positive staining for nucleosomes and histones in the 
deposits in these biopsies is in all likelihood due to the fact lhat 
nucleosome-specific epitopes, in contrast to histone-specific 
epitopes, are masked by autoantibodies bound to these epitopes 
in vivo. Although the biopsy specimen of the patient presented 
today could not be evaluated, a representative example from 
another patient with WHO class IV lupus nephritis shows the 
presence of nucleosomes and histones (Fig. 4). (3) Nucleosome- 
specific antibodies can be eluted from glomeruli [56, 76]. In 
summary, it appears that nucleosomes contribute importantly to 
the development of lupus nephritis by targeting antinuclear 
antibodies to the GBM.
Anti-Clq autoantibodies. In recent years it was found that 
anti-Clq autoantibodies were associated with lupus nephritis. In 
the 1970s, much attention was given to the measurement of 
circulating immune complexes in various diseases [77], Although 
widely employed in those years, these measurements have not 
become a clinically useful tool for the diagnosis and management 
of patients with autoimmune diseases. One of the methods used to 
measure immune complexes was based on the interaction of these 
complexes with the complement component Clq. But not only 
high-molecular-weight material (immune complexes) interact 
with Clq, but also low-molecular-weight 7S material [78], This 
“low-molecular-weight” 7S material was identified as antibodies 
reacting via their antigen-binding site, and not via their Fc part, 
with the collagen-like region of Clq. Although these antibodies 
have been found predominantly in patients with SLE [79], the 
presence of IgG anti-Clq is not restricted to patients with SLE; it 
is also found in patients with mixed connective tissue disease, 
ankylosing spondylitis, polyarteritis nodosa, mixed cryoglobuline­
mia, membranoproliferative glomerulonephritis, anti-GBM ne­
phritis [80], and in older healthy controls [81].
In a retrospective analysis of SLE patients, Siegert et al found 
correlations between the titers of anti-Clq antibodies and the 
occurrence of nephritis, hypocomplementemia, and titers of anti- 
dsDNA antibodies [82]. This group confirmed the correlation with 
nephritis in a prospective analysis; moreover, an increase in serum 
anti-Clq antibodies was followed by the development of a prolif­
erative glomerulonephritis [83]. In the patient presented today, 
we retrospectively measured the level of anti-Clq antibodies in 
the blood samples obtained during the fourth renal flare (Fig. 1) 
according to previously described methods [84], As Figure 2
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prednisone monotherapy had an excellent renal survival. In 
contrast to this, patients with membranous lupus nephritis accom­
panied by proliferative lesions (the former WHO class V.C/V.D; 
see Table 1) had a much worse prognosis, even though most of 
these patients ako had received cyclophosphamide (CPM) or 
AZA [91]. This study clearly indicates that the course of mem­
branous glomerulonephritis formerly classified as WHO class 
V.C/V.D differs from that of membranous glomerulonephritis 
classified as WHO class V.A/V.B. If renal function is impaired or 
deteriorates in a patient with pure membranous lupus glomeru­
lonephritis, one could consider treatment with oral CPM to 
preserve renal function, as suggested for idiopathic membranous 
glomerulonephritis [92]. In contrast to this, monthly intravenous 
CPM pulses did not preserve renal function in prospective 
randomized studies in patients with idiopathic membranous glo­
merulonephritis [93, 94], Unfortunately, no such controlled stud­
ies are available on membranous lupus nephritis, so we do not 
know whether CPM should be used for the treatment of lupus 
membranous glomerulonephritis. If CPM is prescribed, the expe­
rience in idiopathic membranous glomerulonephritis suggests that 
continuous oral administration is preferable over monthly intra­
venous pulses. Because of the lack of data on long-term effects of 
CPM treatment in lupus membranous glomerulonephritis, Appel 
and Valeri suggested that if treatment with CPM is instituted, the 
treatment should be evaluated after six months; if treatment is 
unsuccessful, the drug should be discontinued [90]. The experi­
ence with cyclosporine A  (CsA) in membranous lupus nephritis is 
limited. Although CsA reduced proteinuria in all patients in one 
study, in 4 of 10 patients proteinuria increased again after 
cessation; more worrisome, glomerular lesions progressed in all 5 
patients rebiopsied [95]. Furthermore, CsA induced hypertension 
and nephrotoxicity in one-half of patients, was associated with 
disease flares after drug cessation, and did not influence autoan­
tibody production [96], Although obtained in a small number of 
patients, these results suggest that CsA is not a reasonable 
therapeutic option in SLE.
The occurrence of a pure interstitial nephritis in SLE is rare, 
and the literature contains no therapeutic guidelines for it. We 
can reasonably assume that this condition should be treated like 
other forms of non-SLE acute interstitial nephritis. That is, 
therapy could comprise oral prednisone monotherapy, in severe 
cases preceded by a short course of intravenous methylpred- 
nisolone [97, 98].
For advanced glomerulosclerosis in lupus (WHO class VI), 
intensification of immunosuppression confers no benefits. Treat­
ment for this group of patients focuses on the extrarenal lupus 
manifestations and on alleviating the consequences of chronic 
renal insufficiency (protein restriction, antihypertensive treat­
ment, oral phosphate binders, vitamin D analogues, and erythro­
poietin. substitution). With the good results that renal replace­
ment 'herapy offers patients with SLE, we should not expose 
patients with irreversible renal lesions further to the risk of 
immunosuppression (until the time of transplant).
Cameron analyzed the five-year patient survival of patients with 
WHO class IV glomerulonephritis over the last 40 years and 
noted a steep increase in the early 1970s, from about 25% in the 
decade before to 76%-78% [99]. This improved outlook undoubt­
edly is due to the introduction of cytotoxic drugs (mainly AZA 
and CPM) into the therapeutic armamentarium and to the 
increased availability of dialysis to treat ESRF. A meta-analysis by
Felson and Anderson made it clear that the addition of cytotoxic 
immunosuppressive drugs (AZA or CPM) to prednisone im­
proved renal survival in comparison to treatment with prednisone 
alone [100]. The histologic analysis by Balow and colleagues 
explained this beneficial effect [101]. In repeat biopsies of SLE 
patients treated with prednisone monotherapy, the chronicity 
index increased on average 1.4 points/year; in the AZA- or 
CPM-treated patients, this index remained stable over time. The 
same investigators were the first to report that a chronicity index 
of more than 3 (on a total score of 12) strongly predicted ESRF
[102]. These observations raise the question; which of the two 
cytotoxic drugs, AZA or CPM, is superior? Clinical trials from the 
NIH showed that drug regimens containing either intravenous or 
oral CPM were superior to prednisone alone in terms of prevent­
ing ESRF [103,104]. But AZA, combined with low oral doses of 
prednisone, did not significantly differ from CPM-containing 
regimens or from prednisone monotherapy. Further, the NIH 
studies showed that a regimen of monthly intravenous pulses of 
CPM was comparable to continuously used oral CPM in terms of 
efficacy, but was less toxic [103]. Although desperately needed, no 
further controlled trials have compared CPM and AZA in terms 
of efficacy and toxicity.
Cameron [99] tried to overcome this lack of information by 
comparing both the renal and patient survival of patients with 
diffuse proliferative lupus nephritis treated with either CPM [103] 
or AZA [99, 103, 105-107] and found no differences in either 
renal or patient survival. Cameron’s comparison conforms with 
the results of the NIH studies, which also found no differences 
between CPM and AZA [103, 104], The superiority of CPM over 
AZA thus has not been proven. This conclusion is important in 
view of the severity and higher frequency of side effects of CPM. 
Treatment with CPM is associated with amenorrhea in 50% to 
70% of patients after long-term oral use and in 30% after 
intravenous administration of CPM pulses [108], In patients given 
intravenous pulses of CPM, the incidence of amenorrhea in­
creases with the number of pulses and the patient’s age [108]. The 
fear of this side effect caused the patient presented today to refuse 
treatment with CPM on three occasions. Data on the effect of 
CPM on spermatogenesis are curiously lacking. One report about 
CPM therapy for nephrotic syndrome due to minimal-change 
disease suggests a threshold of 12 to 17 g as the cumulative dose 
above which oligospermia can occur [109]. These data contrast 
sharply with the effects of AZA on gonadal function. Experience 
gained from renal transplant patients indicates that AZA does not 
affect reproductive ability both in men and women. Even preg­
nancies during which AZA is administered are relatively safe, 
showing only a slight increase in congenital malformations [110]. 
In contrast, giving CPM during pregnancy is absolutely contrain­
dicated because of its strong teratogenic potential. Uro-epithelial 
toxicity, ranging from hemorrhagic cystitis to invasive bladder 
carcinoma, is also a unique side effect of CPM. This complication 
occurs more frequently after oral than after intravenous admin­
istration of CPM and is related to the total cumulative dose [103, 
i l l ] .  Treatment with long-term oral CPM is associated with the 
development of hemorrhagic cystitis in 17% of lupus patients
[103] and in 43% of patients with Wegener’s disease [112], In this 
latter group of patients, 2.8% developed bladder cancer, which 
represented a 33-fold increase in the risk for this complication. An 
increased frequency of other malignancies, mainly non-Hodgkin’s 
lymphoma (relative risk: 10.9) and skin cancers (relative risk: 5),
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is observed during treatment with AZA or CPM [113]. Although 
we have no good data that compare the carcinogenic potential of 
these drugs, we have more long-term experience with AZA.
In addition to oral prednisone, AZA, or CPM, another thera­
peutic modality frequently employed in the treatment of lupus 
nephritis is intravenous pulses of high doses of methylpred- 
nisolone (ivMP). These high dosages of steroids likely have a 
more rapid and a stronger effect on the inflammatory and 
autoimmune response than does oral prednisone [89], A number 
of uncontrolled studies [reviewed in Ref. 89] and one controlled 
study [114] showed that ivMP in conjunction with low doses of 
oral prednisone promptly improved renal function and autoim­
mune parameters in most patients, but the effect on proteinuria 
took longer. These studies also suggested that the ivMP/low-dose 
oral prednisone regimen had higher efficacy combined with lower 
toxicity when compared to high oral doses of prednisone alone. 
None of these studies, however, established the Jong-term effect of 
ivMP on the preservation of renal function. The histologic fol- 
lowup study by Balow et al [101], which evaluated oral prednisone 
treatment, raises the question whether treatment with steroids 
alone can prevent the progression of chronic lesions. Indeed, a 
prospective randomized study from the same group compared six 
monthly ivMP pulses with intravenous pulses of CPM adminis­
tered for six months (6 pulses) or 30 months (14 pulses) and found 
that treatment with ivMP was associated with a significantly 
greater risk for deterioration of renal function and a higher 
relapse rate than treatment with CPM pulses [115]. Thus ivMP 
alone, without cytotoxic drugs, constitutes insufficient treatment.
What conclusions can we draw from these studies? First, it has 
not been proven that AZA is less effective than CPM, but it is 
certainly less toxic. Second, in the initial treatment of lupus 
nephritis, ivMP is as good as high dosages of oral prednisone (1.0 
mg/kg) but has fewer side effects. Therefore, a combination of 
AZA (which prevents progression of chronic lesions) and an 
induction treatment with ivMP (which rapidly induces regression 
of the acute lesions) might be an ideal combination, combining 
efficacy with less toxicity. A recent report from the Academic 
Medical Center of the University of Amsterdam showed, unfor­
tunately in an uncontrolled study, that this combination therapy is 
effective and associated with little toxicity [116]. Thirteen patients 
with recent-onset (median duration, four months) diffuse prolif­
erative lupus nephritis (mean serum creatinine, 109 ¿¿mol/liter 
(1.2 mg/dl); GFR, 58 ml/min) were treated with three courses of
1 g ivMP given three times (2 and 4 weeks apart), 20 mg oral 
prednisone, and 2 mg/kg AZA. This regimen improved renal 
function in all patients (mean serum creatinine, 68 jumoí/liter (0.7 
mg/dl); GFR, 102 ml/min at mean followup of 7 years), reduced 
proteinuria (only four had 1.0-1.5 g/24 hr at last followup), and 
improved serologic parameters. Side effects occurred in two 
patients: re-entry tachycardia and septicemia. Although herpes 
zoster developed in one patient, no other major bacterial, viral, or 
opportunistic infections occurred. The promising results of this 
uncontrolled study prompted the Dutch Working Party on SLE to 
embark recently on a national, prospective randomized trial 
comparing intravenous pulses of CPM (6 monthly pulses, and 
quarterly pulses for the following 18 months) and high oral doses 
of prednisone (1 mg/kg) with the combination therapy of ivMP, 
prednisone, and AZA [as described in Ref. 117]. The results of 
this study should provide more definitive conclusions regarding
the efficacy and side effects of CPM/prednisone versus AZA/ 
prednisone treatment,
Finally, let me say a few words about the therapeutic potential 
of plasmapheresis in lupus nephritis. Although two groups 
claimed positive short-term effects in uncontrolled studies [118, 
119], subsequent randomized trials failed to confirm their enthu­
siasm [120, 121]. A large-scale, prospective randomized trial 
provided a definitive answer regarding the efficacy of plasma­
pheresis [122]. The addition of plasmapheresis to immunosup­
pressive therapy did not confer a significant benefit. Although the 
results of a prospective German study employing sequential 
plasmapheresis and intravenous CPM are not yet available [123], 
it seems justifiable to conclude on the basis of current information 
[124], that plasmapheresis is not a useful adjunct to immunosup­
pressive therapy in patients with lupus nephritis.
Intensification of immunosuppressive treatment is generally 
indicated if a renal flare develops. The identification of such an 
exacerbation usually is based on changes in clinical parameters, 
such as an increase in hematuria or proteinuria, or a deterioration 
of renal function. The observation that 89% of renal and non- 
renal disease flares occur 10 weeks after a significant rise of the 
anti-DNA titer [6] led Kallenberg’s group to investigate whether 
these relapses can be prevented by increasing the prednisone 
dose, irrespective of clinical symptoms, if such a rise in anti- 
dsDNA occurs [125]. Anti-dsDNA titers were measured monthly 
with the Farr assay. If the anti-DNA titer rose more than 25%, 
patients were randomly assigned to either continuation of their 
current medication or to a 30 mg increase of their current 
prednisone dose. The titer rose significantly in 46 of 156 patients; 
24 were randomized for continuation of their existing medication, 
and 22 patients were given an increased prednisone dose. The 
relapse rate was higher in the group with unchanged medication 
than in the prednisone group (20 versus 2, P  <  0,001), but a 
significant difference was noted (P <  0.001) only for minor 
relapses and not for major relapses (P = 0.12). Renal relapses 
occurred five times in the conventional treatment group and two 
times in the prednisone group; this difference was not significant. 
Furthermore, this approach did not lead to a difference in the 
cumulative or mean daily dose of prednisone after randomization. 
Therefore one has to conclude that this serologically guided 
treatment protocol cannot prevent renal relapses. It remains to be 
determined whether the use of a different serologic marker 
(possibly nucleosome-specific antibodies or ami-Clq antibodies) 
can yield more favorable results.
Renal replacement therapy in SLE
Progi'ession to end"stage renal failure. The patient presented 
today developed ESRF within four years. Nossent’s recent review 
of the literature indicates that this complication develops in 
approximately 20% of the patients with lupus nephritis (Table 2) 
[126]. These data suggest that the incidence of ESRF has been 
relatively stable over the last three decades. In most studies, the 
mean time between onset of lupus nephritis and ESRF is five 
years [127, 128]. Nossent and colleagues in cooperation with the 
Dutch Working Party on SLE studied 55 SLE patients who 
developed ESRF [128]. These patients had at least one, and 
sometimes more, renal flares after the onset of nephritis, as did 
the patient presented here. The standardized SLE Disease Activ­
ity Index (SLEDAI) [129] applied at three-month intervals re­
vealed that in the period preceding ESRF, 15% of the scores were
546 Nephrology Forum: Lupus nephritis
Table 2. Percentage of SLE patients with glomerulonephritis 
developing end-stage renal failure (ESRF) during the last four decadesa
Time period
Number of 
patients with 
lupus nephritis
Number of 
ST ,F, patients 
with ESRF Percentage
1950-1960 54 26 48.1
1961-4970 301 40 13.3
1971-1980 601 145 24.1
1981-1992 317 58 18.3
All periods 1273 269 21.1
a Recalculated from data reviewed in Ref. 126.
Table 3, Factors associated with an increased risk for the development
of end-stage renal failure in SLE
Factor Reference
Elevated initial serum creatinine (in most 
studies >  100 /¿mol/liter, 1.1 mg/dl) 
Nephrotic-range proteinuria 
Low C3
Hematocrit ^  26%
Hypertension 
WHO class IV 
Activity index ^ 1 2  
Chronicity index ^  3 
No normalization of elevated serum 
creatinine at 48 weeks 
Treatment with prednisone only 
Persistent disease activity 
Male gender 
Black race 
Age <  24 years 
Low socioeconomic status
[91, 105, 133, 140-144]
[105, 144, 145]
[105, 143, 146]
[143, 146]
[143]
[102, 105, 133,140, 147] 
[102, 140, 142, 143]
[102, 105, 140,142, 143] 
[141]
[100, 104, 148]
[105, 126] 
r128, 135, 140]
Ì43 , 146, 149, 150] 
[105, 140]
[149]
high (>: 10) and 51% were moderately high. The regression line of 
all SLEDAI scores over time prior to dialysis showed a slow but 
significant rise. These observations indicate that, in general, this 
group of patients had active disease before reaching ESRF. 
Furthermore, in the period before reaching ESRF, disease quies­
cence is exceptionally rare in lupus patients progressing to renal 
failure [126]. Therefore, as one would expect, persistent or 
remittent disease activity is a major risk factor for ESRF.
The literature cites a number of other factors that increase the 
risk for ESRF in patients with lupus nephritis (Table 3). Not all 
these parameters have been confirmed in all studies, probably 
because of differences in definitions used, composition of the 
cohort studied, duration of the followup, and the number of 
patients included. Many of these risk factors were present in 
today’s patient: hypertension, nephrotic-range proteinuria, low 
C3, WHO class IV, activity index ^ 1 2 ,  remittent disease activity, 
and age ^  24 years).
Dialysis. Hemodialysis initially was not offered to lupus nephri­
tis patients because of the systemic nature of their illness. But in 
the early 1970s, it became clear that these patients tolerated 
hemodialysis treatment as well as did patients with non-SLE renal 
diseases [130], Survival rates for patients with lupus were initially 
lower in some [131], but not all studies [132], however. This 
increased mortality rate was mainly due to infections secondary to 
continued immunosuppressive treatment. At present, the five- 
year survival rate of SLE patients treated with dialysis is at least as 
good as that for the non-lupus population, and ranges between
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Fig, 5. Actuarial patient survival of 55 SLE patients who progressed to 
end-stage renal failure (ESRF pos) compared with that of 92 SLE patients 
who did not develop end-stage renal failure (ESRF neg). The survival 
curves were not significantly different. Time point zero represents the 
onset of lupus nephritis. (Reproduced with permission from Ref. 126.)
80% and 90% [127, 128]. Because the prognosis during dialysis 
treatment is relatively so good in patients with SLE, it is no longer 
necessary to prevent ESRF at all costs in patients with already 
impaired renal function. Although intensification of immunosup­
pression decreased the cumulative incidence of ESRF in some 
studies, it did not improve patient survival rates [104, 133], 
Actually, in the lupus nephritis studies by the Dutch Working 
Party on SLE, patient survival calculated from the onset of lupus 
nephritis was similar for patients with lupus nephritis who did 
(n = 55) or did not (n = 92) reach ESRF (Fig. 5) [126]. These
data clearly show that dialysis is not associated with a higher 
mortality when compared to aggressive therapy of far advanced 
lupus.
What is the influence of dialysis on lupus disease activity? 
Before addressing this question, we should note that sometimes it 
is difficult to determine whether a certain condition (for instance, 
pericarditis) is an ESRF-related manifestation or an expression of 
lupus disease activity. Given this limitation, we can say that 
disease activity generally decreases during dialysis, although dis­
ease manifestations can persist or even develop, especially in the 
first year after the start of dialysis [126]. Nossent and colleagues 
compared in 55 SLE patients undergoing dialysis treatment— 
either hemodialysis (n = 32) or CAPD (n = 23)—the maximal 
non-renal SLEDAI scores before and after the start of dialysis, 
and found that this score decreased significantly (P <  0.001) after 
dialysis was started [128]. In 49% of the patients, maximal 
non-renal disease activity decreased, in 42% remained stable, and 
only in 9% showed progression [128]. No differences were found 
between patients treated with hemodialysis or CAPD. The SLE­
DAI is the most sensitive index for measuring changes in SLE 
disease activity over time [134]. Nossent et al used another 
estimate of disease activity, the time-adjusted event rate of 
specific disease manifestations, and discerned no significant dif­
ferences in disease activity between the periods before and after 
the start of dialysis, although the events during dialysis occurred 
during minimized immunosuppression [128]. For instance, aza- 
thioprine or cyclophosphamide administration was stopped in
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Fig. 7. Lupus disease activity in 28 SLE patients who received a renal 
allograft. Disease activity was assessed by the maximal non-renal SLEDAI 
before (■) and during ((Ü) dialysis and after renal transplantation (□ ). 
The SLEDAI scores were divided in three groups: 0, no disease activity; 
1-10, moderate disease activity; and >10, high disease activity. Note that 
prior to dialysis none of these patients had absent disease activity, but after 
renal transplantation none of the patients had high disease activity. 
(Figure drawn from data published in Ref. 135.)
90% of the patients, and the prednisone dose was considerably 
reduced in 55%.
Renal transplantation. The patient presented in this Forum did 
very well after renal transplantation. She had only a borderline 
acute graft rejection three months after transplantation and no 
major lupus manifestations during a followup of 4 years. Is her 
course a fair general representation of all lupus patients after 
renal transplantation? In our Dutch survey on renal transplanta­
tion in lupus patients, both the one- and three-year graft survival 
was 68%, and patient survival was 87% [135]. Graft survival was 
somewhat lower than that generally achieved nowadays. However, 
patient data were collected over an eight-year period, from 1980 
to 1988, and one-half of the patients received transplants before 
the routine use of cyclosporine A as a basic immunosuppressive 
drug. More recent data obtained from Euro transplant show that 
graft and patient survival rates for SLE patients after renal 
transplantation are not significantly different from those for 
patients with non-SLE glomerular diseases (Fig. 6). Similar results 
have been reported in the literature [136-138].
What happens to SLE disease activity after renal transplanta­
tion? In general, disease activity declines further. In the Dutch 
analysis, the majority of patients (72%) had no disease activity 
after renal transplantation, as judged by SLEDAI scores every 
three months during a median followup of 31.5 months (range, 
3-89 months) [135]. Figure 7 compares disease activity (using 
maximal non-renal SLEDAI scores) before dialysis, during dialy­
sis, and after renal transplantation in SLE patients. It is interest­
ing that high lupus disease activity before or after the start of 
dialysis, a duration of dialysis of less than 12 months, or a high 
antilymphocyte reactivity before transplantation did not adversely 
affect graft survival. In only one patient was a recurrence of the 
original disease diagnosed. In a recent survey of the literature, 5 
of 321 patients showed recurrence of lupus nephritis after renal 
transplantation [126], If this total number is corrected for the 
patients who lose their grafts within the first year, the calculated
cumulative incidence of recurrent disease is 1.9%. This experience 
contrasts with a report from Nyberg and colleagues, who found 
signs of recurrence in electively taken transplant biopsy specimens 
in 7 of 16 SLE patients (43%) [139]. The choice of the parameters 
they used to define recurrence—namely, mesangial proliferation 
and deposition of IgM and C3—is debatable, because these 
features are not specific for lupus nephritis, especially in trans­
plant biopsies. Thus, most of the literature suggests that in 
general, lupus patients have a reduction of disease manifestations 
and a very low risk of recurrence after transplantation. It remains 
intriguing why these patients respond so well after transplanta­
tion, since they are usually treated with the same kind of drugs 
that failed to control their disease before transplantation. In 
summary, dialysis and renal transplantation are good treatment 
modalities fur SLE patients with ESRF. During renal replacement 
therapy, lupus disease activity generally subsides, and the likeli­
hood of recurrence of lupus nephritis after renal transplantation is 
low.
QUESTIONS AND ANSWERS
Dr. N ic o l a s  E. M a d i a s  (Chief, Division o f Nephrology, New 
England Medical Centeri Boston, Massachusetts): What do we 
know about the nature of the nucleosomal epitopes that appear to 
drive the autoimmune response in systemic lupus erythematosus?
D r , B e r d e n : This is an important question. Since it is difficult 
to analyze these epitopes with polyclonal auto-antibodies, we and 
others have tried to circumvent this problem by analyzing the 
antigen specificity of different nucleosome-specific monoclonal 
antibodies [151-154]. These analyses revealed that H2A'H2B/ 
DNA seems to harbor the major epitopes and, to a lesser extent, 
also H3-H4/DNA. Time studies, mainly in lupus mice, indicate 
that antibodies to H2A-H2B/DNA are formed earlier in the 
disease than are those against H3-H4/DNA [26, 55]. We also 
tested these monoclonal antibodies on 53 partly overlapping 
synthetic peptides, covering all his tone proteins, and found with
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one exception (peptide 83-100 from histone H3) no or only very 
low reactivity; thus, linear epitopes probably are not very impor­
tant [60, 151]* Because some of these monoclonal antibodies react 
better with the total riucieosome than with subnucleosomal struc­
tures, additional epitopes might exist that are still undiscovered 
[151], These data confirm previous observations that nucleosome- 
specific antibodies recognize conformational epitopes created by 
the interaction between DNA and histones. Relevant epitopes 
might not be expressed by native nucleosomes but are only 
presented on altered nucleosomes. These alterations (protein 
modification/fragmentation) can be induced by oxygen radicals 
produced during aberrant apoptosis [47, 48]. These novel 
epitopes, not expressed on native nucleosomes, are then recog­
nized by T-cells. At the moment we are probing these possibilities 
by using nucleosomes released from normal and lupus-derived 
apoptotic cells as antigenic targets. This investigation might 
elucidate the driving epitope within the nucleosome. Recently 
Datta’s group localized three regions in the core histones 10-33 
H2B, 16-39 H4, and 71-94 H4 that acted as epitopes for 
pathogenic T-helper cells [155].
D r. M a d i a s : As you know, Madaio and coworkers have isolated 
a number of monoclonal antibodies with anti-DNA activity from 
various murine models of SLE [15]. These antibodies exhibit 
differences in their level of nephritogenicity. Further, individual 
nephritogenic antibodies consistently display a distinct pattern of 
glomerular injury. Could you please reconcile these observations 
with the nucleosomal theory?
D r. B e r d e n : We think that these observations are due to the 
fact that these monoclonal antibodies are complexed to a variable 
degree to nucleosomes, depending on the specificity of the 
monoclonal antibody and the hybridoma culture conditions. As 
we have shown, it is sometimes very difficult to remove all the 
complexed nucleosomal material [21]. After purifying anti-nu­
clear monoclonal antibodies and carefully checking for remaining 
nucleosomal impurities (with 32P radiolabeling to detect DNA 
and agarose gel electrophoresis with double silver staining to 
detect histones), we never found glomerular localization with 
purified antibodies [21]. Also, cross-reactive binding of monoclo­
nal anti-nuclear antibodies to other non-DNA antigens like 
heparan sulfate was abrogated by this purification [17]* The 
observation from Dr. Madaio’s group that such a cross-reactivity 
[14] is a distinguishing feature of their nephritogenic monoclonal 
antibodies [156, 157] strongly, albeit indirectly, indicates that 
complex formation with nucleosomes is instrumental for induc­
tion of glomerular deposits.
Another line of evidence indicates that Madaio’s monoclonal 
antibody preparations are complexed to nucleosomes. These 
investigators reported that several of their monoclonal antibodies 
are able to penetrate cells and to localize into the nucleus [158], 
We [159] and others [160] have shown recently that this intracel­
lular uptake of autoantibodies critically depends on the presence 
of nucleosomal material bound to the antibody, since purified 
antibodies did not bind and were not internalized. In our hands, 
the observed nuclear localization was a fixation artifact; if we 
prepared the kidney with perfusion-fixation with PLP (periodate 
lysine-paraformaldehyde) instead of using tissue fixation with 
acetone, we found not nuclear but cytoplasmic localization, 
similar to that observed with confocal laser microscopy in living 
cells [159]. Although this in-vivo ANA phenomenon is artifactual, 
we agree with Dr. Madaio and his coworkers that the induction of
glomerular deposits is characteristic for pathogenic and nephrito­
genic autoantibodies, because it is displayed by autoantibodies 
complexed to nucleosomes. These same nucleosome-complexed 
autoantibodies can bind to the GBM in vivo [21] and are related 
to the onset [161] and exacerbation [162] of lupus nephritis in 
patients with SLE. Also, Ohnishi and colleagues concluded that 
pathogenic anti-DNA antibodies can: (I) bind to the GBM via 
histone/DNA (nucleosomes), and (2) display an in-vivo ANA 
phenomenon after acetone tissue fixation [163].
So, to summarize a long answer, both our and Dr. Madaio’s 
results are consistent with the fact that certain anti-nuclear 
antibodies can induce glomerular deposits, but our explanations 
for this glomerular binding differ. They attribute their observa­
tions to direct cross-reactive binding of monoclonal antibodies to 
the GBM and cell-surface constituents; we have convincing evi­
dence that these reactivities are mediated by nucleosomes.
D r . B e h r o o z  B r o u m a n d  (Professor o f Medicine, University of 
Medical Sciences o f Iran, Teheran, Iran): I have three questions. 
First, after transplantation most patients with SLE are treated 
with prednisone, azathioprine, and cyclosporine. Moreover, after 
renal transplantation, disease activity generally declines. Maybe it 
would be wise to formally study these drugs to evaluate whether 
they are better than either prednisone and cyclophosphamide or 
prednisone and azathioprine for the treatment of lupus nephritis. 
Second, do you think that ACE inhibitors could be used in the 
treatment of lupus nephritis? Besides decreasing blood pressure, 
they could reduce proteinuria and prevent further tubulo-inter- 
stitial damage. Finally, do you see any future for gene therapy— 
for instance, manipulating Bcl-2 or BAX expression in order to 
influence apoptosis?
D r . B e r d e n : To answer your first question, only limited 
experience, in uncontrolled studies, with cyclosporine in the 
treatment of class-IV or class-V lupus nephritis has been re­
ported, and the results are not very convincing [164, 165]. What 
worries me about the use of cyclosporine for the treatment of 
lupus nephritis is that it has no effect on autoantibody formation 
either in humans [164] or in spontaneous murine lupus models 
[166], And as mentioned, repeat biopsies during treatment with 
cyclosporine showed progression of histologic abnormalities [95] 
despite the fact that proteinuria declined. In my opinion, there is 
no place for cyclosporine in the treatment of lupus nephritis. You 
are correct that disease activity declines after renal transplanta­
tion in the majority of patients, but improvement has already 
begun during dialysis and before transplantation. Thus the “burn­
out” of the disease is not due to post-transplant immunosuppres­
sion, but rather originates during dialysis. There is no satisfactory 
explanation for this “burn-out.”
Your second question relates to the use of ACE inhibitors in 
patients with lupus nephritis. It's certainly true that inadequate 
blood pressure control in patients with lupus nephritis will 
quicken the deterioration of renal function. I am not aware of any 
study in lupus patients showing that ACE inhibitors are superior 
in this respect to beta-blockers or calcium-entry blockers. We do 
know that ACE inhibitors reduce proteinuria [167] and thus could 
slow the progression of tubulo-interstitial damage [168], Austin et 
al recently showed that, indeed, tubulo-interstitial lesions, as in 
other glomerular diseases [169], are strong predictors for the 
development of end-stage renal failure [143]. Any measure that 
reduces this interstitial burden is therefore beneficial.
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Your last question related to gene therapy. I do not think that 
gene treatment to influence Bel-2 expression is currently feasible, 
because the margins for this approach seem rather small. In 
experimental animals, transgenic overexpression of Bcl-2 lead to 
auto-immunity [38]; in Bcl-2 knockout mice, a dramatic involution 
of the immune system is observed soon after birth [170, 171], In 
my opinion a more realistic approach would be a search for 
nucleosome-derived peptides that could “turn off” the pathogenic 
auto-immune response. A similar approach has been successful in 
a number of auto-immune models, such as adjuvant-induced 
arthritis [172].
D r . M a r ia n  K linger  (Professor o f Renal Medicine, Department 
of Nephrology, University School o f Medicine} Wroclaw, Poland): 
Your point against cyclophosphamide was very strong, but cyclo­
phosphamide toxicity very much depends on cumulative doses. 
Why not start with intravenous cyclophosphamide, administer 
doses of, let’s say, up to 100 mg/kg, and later support the 
remission with azathioprine? One remark: I noticed that the 
prednisone dose in your prospective protocol, 1 mg/kg, is higher 
than the dose of 0,5 mg/kg used in the original NIH protocol, so 
the risk of undesired prednisone effects is greater. Finally, you did 
not mention in your choices of therapy so-called “synchronized 
plasmapheresis.” D o  you believe that it is worth a trial?
Dr. B e r d e n : I did not understand your first point. Did you 
propose to give cyclophosphamide at 100 mg/kg?
D r . K ling er: I propose to start with standard intravenous 
cyclosphamide doses and administer it until a cumulative dose of 
100 mg/kg—which is, T believe, without major long-term toxici­
ty—is reached and later try to support the remission with azathio- 
prine.
D r . B e r d e n : The protocol that you describe with initial cyclo­
phosphamide and subsequent azathioprine has been used by a 
number of groups both for lupus and non-lupus glomerular 
diseases [122, 173], Your presumption is that cyclophosphamide 
treatment is better, but you want to reduce the side effects. I think 
the NIH data force us to conclude that cyclophosphamide is not 
superior to azathioprine. So I don’t believe that a six-month 
induction treatment, which does not exceed the cumulative dose 
you mentioned, is advantageous over the combination of intrave­
nous methylprednisolone and azathioprine. Still, we have no 
controlled data to support either your or my approach.
You asked about the predisone dose. The two publications 
from the NIH group are not veiy specific about the prednisone 
dose they use [103, 104]. The different reports use between 0.5 
mg/kg and 1 mg/kg, but in general they did start with 0.5 mg/kg. 
However, in our protocol, we taper the dose rapidly, and our 
cumulative cyclophosphamide dose is lower (24 months of treat­
ment instead of 30 months).
Your last question about synchronized plasmapheresis is very 
current. In 1990 the group of Euler in Kiel started a trial using 
synchronized plasmapheresis and cyclophosphamide. The results 
have not yet been published, but I recently heard that they will 
become available soon. Theoretically, this approach is attractive, 
because plasmapheresis stimulates the B-cell, which makes it 
more susceptible to the cytotoxic drug given subsequently. We 
have to wait for the results of this trial before coming to any 
conclusions about this approach.
D r . M a d ia s: S o m e  cases o f  lupus are accom panied  by a 
throm botic vascu lopathy w ith glom erular and vascular throm bi, 
often in association  w ith a lupus anticoagulant, the clinical picture
being akin to that of thrombotic thrombocytopenic purpura. Are 
you of the opinion that plasmapheresis with plasma infusion 
should not be used even in that setting?
D r . B e r d e n : Some lupus patients do have renal vascular 
abnormalities in conjunction with anti-phospholipid antibodies. In 
general no correlation exists between the presence of anti­
phospholipid antibodies and the development of lupus nephritis 
[174, 175] but, as you said, thrombi can develop in the renal 
vasculature [175, 176], No data regarding optimal treatment are 
available; all reports have been anecdotal. We treat these patients 
with oral anticoagulants. We don’t treat them differently with 
regard to the immunosuppressive regimen unless glomerulone­
phritis is absent. These patients, who do not have inflammatory 
glomerular lesions, sometimes present with acute renal failure, 
often accompanied by malignant hypertension. This condition has 
been called the “catastrophic anti-phospholipid syndrome” [177], 
Plasmapheresis combined with adequate anticoagulation is cur­
rently the treatment of choice for these patients [177].
Dr. S. C. Dash (Professor o f Nephrology, All India Institute o f  
Medicine Sciences; NewDelhi} India): Do you use a threshold value 
for the histologic activity and/or chronicity index above which you 
start treatment with cytotoxic drugs?
D r . B e r d e n : We base our decision for treatment with cytotoxic 
immunosuppressive agents only on the World Health Organiza­
tion classification (either class III or IV), although the WHO 
classification does correlate with the NIH scoring system. In our 
retrospective analysis [142], we found a mean activity and chro­
nicity index, respectively, for class III of 4.6 and 3.2, and for class 
IV of 8.1 and 3.9; for class II and V, these indices were much 
lower. Of course, it would be nice to have the results of a study in 
which you could further refine your therapy based on histologic 
criteria like the activity and chronicity indices. But it will be very 
difficult to perform a study in which patients are stratified 
according to NIH activity and chronicity indices. It is difficult 
enough to carry out a trial based on the WHO classification, as 
evidenced by the low number of controlled studies available. The 
only situation in which we take the NIH score into account is if the 
patient has advanced sclerotic glomerular lesions and a high 
chronicity index. The majority of these patients are categorized as 
WHO class VI. We are reluctant to prescribe cytotoxic drugs in 
this group because we don’t anticipate much of a functional 
benefit.
D r . M ike V e n n in g  (Consultant Renal Physician, Withington 
Hospital, University Hospital o f South Manchester; Manchester; 
England): I am concerned that you might have drawn some 
conclusions that are not fully warranted by the evidence, specifi­
cally with reference to the size of the trials and a lack of power to 
support negative conclusions. From conversations a few years ago 
with Dr. Balow, I understand that he believes cyclophosphamide 
to be a better therapy than azathioprine for lupus nephritis. 
Further, clinical experience with patients who have responded to 
cyclophosphamide after having relapsed or failed to achieve 
control with azathioprine therapy also suggests that active lupus 
nephritis is better treated with cyclophosphamide. The NIH study 
did not have sufficient power to determine whether cyclophospha­
mide is better than azathioprine.
Similarly, clinical experience with chronic ambulatory perito­
neal dialysis (CAPD) in lupus patients suggests that the risk of 
peritonitis or exit-site infection is high following immunosuppres­
sion, particularly when high doses of steroids have been used. I am
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concerned that sufficient data are not available to demonstrate the 
equivalent effectiveness of hemodialysis, which I believe to be 
better in this setting, and CAPD.
D r . B e r d e n : I cannot exclude the possibility that the NIH 
studies are flawed by a class-II error, especially because the 
number of patients treated with azathioprine was rather small. 
But studies other than the NIH investigation have shown no 
conclusive differences between azathioprine and cyclophospha­
mide in the treatment of lupus nephritis [99,100]. Actually, in the 
meta-analysis by Felson and Anderson, azathioprine preserved 
renal function better, and was associated with a lower number of 
deaths due to non-renal causes, than did cyclophosphamide [100]. 
Indeed, although our NIH colleagues advocate cyclophosphamide 
therapy, their results do not prove that cyclophosphamide treat­
ment is better.
Your second comment suggested that hemodialysis is better 
than CAPD in patients with lupus. Clearly, CAPD bears the 
intrinsic risk of peritonitis and exit-site infections, possibly due to 
immunosuppression. But as I said, our policy—and I think that 
this is true for most clinics—is to reduce immunosuppression as 
soon and as quickly as possible. With this policy we have not 
observed any difference in our comparison between hemodialysis 
(n = 32) and CAPD patients (n = 23) in terms of survival, lupus 
disease activity, and complications. The incidence of peritonitis in 
lupus patients did not differ significantly from that in the non­
lupus population. Cheigh et al came to the same conclusion [178].
Dr. V e n n in g : But again this might be subject to a class-II error 
and perhaps needs further study.
D r . B e r d e n : Maybe, but to my knowledge our study is the 
largest study available.
D r . Sa n  d o r  S o nk o di (Professor o f Medicine and Nephrology, 
First Department o f Medicine, Albert Szent-Gydrgyi Medical Univer­
sity, Szeged, Hungary): May I go back to the question of cytotoxic 
treatment? In your opinion, what is the value of chlorambucil in 
the treatment of lupus nephritis? As you know, chlorambucil has 
fewer side effects than cyclophosphamide.
Dr. B e r d e n : I don’t know whether it is true thal chlorambucil 
has fewer side effects than cyclophosphamide. Furthermore, there 
are no solid data available abom the efficacy of this drug in the 
treatment of lupus nephritis [164, 179], Although we do not have 
experience with chlorambucil in lupus nephritis, it has been used 
in our department for the treatment of idiopathic membranous 
glomerulonephritis [93]. In this prospective trial, in which we 
compared chlorambucil with cyclophosphamide given intrave­
nously, patients did not have fewer side effects with chlorambucil 
than with cyclophosphamide. So I prefer cyclophosphamide over 
chlorambucil. But again, there are no controlled studies compar­
ing these two drugs In lupus nephritis.
D r . M a d ia s : D o y o u  e n v is io n  a ro le  for n ew er drugs, such  as 
rapam ycin , m y c o p h e n o la te , or FK506, in the m a n a g em en t o f  
lu n u s nephritis?
D r . B e r d e n : Of the drugs you mentioned, I think mycopheno- 
late has the best potential. It has a much more profound effect on 
antibody production by B-cells than does azathioprine or cyclo­
phosphamide. If the formation of autoantibodies is instrumental 
for the development of the different tissue lesions, this effect 
might be an important advantage. In addition, mycophenolate has 
anti-inflammatory effects, mainly because it inhibits the recruit-
matory site [180,181]. Rapamycin and FK506 are also potentially 
interesting drugs, although their effects on antibody production 
are less well established. All three drugs have shown beneficial 
effects on the autoimmune disease in MRL/lpr and (NZBxW)Ft 
lupus mice [182-184].
Dr. M a d ia s: How do you manage patients whose disease is 
resistant to conventional therapy?
D r . B e r d e n : It depends on the degree of renal function and the 
previous treatment. If the patient has received several courses of 
induction treatment with immunosuppressive drugs, has poor 
renal function, and a renal biopsy shows extensive chronic lesions, 
we prepare the patient for dialysis and renal transplantation. New 
cases are currently enrolled in the Dutch prospective trial com­
paring cyclophosphamide pulses with intravenous methylpred- 
nisolone, low-dose oral prednisone, and azathioprine. If it is a first 
manifestation or a first flare and the patient fails to respond, we 
switch to the other arm of our protocol. Before we started this 
prospective trial, we added plasmapheresis to the treatment of 
resistant cases, but after the results of the plasmapheresis trial 
became available [122], we stopped doing so.
Dr, B i-iarat  V. S hah  (Head o f Nephrology Section, RD. Hinduja 
National Hospital, Mumbai, India): You reserve treatment with 
cytotoxic drugs mainly for patients with class-III and class-IV 
lupus nephritis. Don’t you think that a class-II nephritis can 
progress to class-III or -IV, and that by giving cytotoxic treatment 
one can prevent this progression?
D r. B e r d e n : You are right that transition from class-II to 
class-III or -IV has been documented [4]. However, this transition 
is generally accompanied by a worsening of clinical signs and 
symptoms—either the appearance of a nephritic sediment, an 
increase in or reappearance of proteinuria, deterioration of renal 
function, or hypertension. So one should monitor a patient with 
class-II lupus nephritis for these changes. If the patient’s clinical 
status does decline, a repeat renal biopsy is indicated to document 
whether class-III or -IV disease has developed. If this is the case, 
treatment with cytotoxic drugs should be started. Prescription of 
cytotoxic drugs to every patient with class-II lupus nephritis leads 
to overtreatment in the majority of these patients; the greatest 
proportion respond adequately to prednisone monotherapy.
D r. F ernando  V a ld er r a ba n o  (Professor o f Medicine, Head, 
Department o f Nephrology, Hospital General Universitario Gregorio 
Marahon, Madrid, Spain): You showed clearly that lupus activity 
decreases in patients with SLE when they develop end-stage renal 
disease, a decrease probably owing to depression of the immune 
response in severe renal failure. On the other hand, treatment 
with recombinant human erythropoietin can improve the immune 
response in patients with end-stage renal disease [185, 186], In 
your experience, does erythropoietin therapy reactivate disease 
activity in lupus patients undergoing dialysis?
D r . B e r d e n : I have never seen this in our patients, nor am I 
aware of such an observation in the literature. Has anyone in the 
audience had such an experience?
D r . V a ld e r rAb a n o : We have monitored five hemodialysis 
patients in whom lupus nephritis was the primary renal disease. 
Erythropoietin therapy did not stimulate disease activity in any of 
them; followup was 6 to 36 months. Also, a 1994 report from 
Hebert et al found that administration of recombinant erythro-
ment of neutrophils, lymphocytes, and monocytes to the inflam- poietin did not alter serologic parameters (C3 levels, ANA,
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anti-dsDNA), or clinical disease markers (serum creatinine, uri- 
nalysis, proteinuria) in five SLE patients who had slightly im­
paired renal function (serum creatinine 150 jumol/liter, 1.7 mg/dl)
[187].
Dr. K.S. Nayak (Chief o f Nephrology, Appollo Hospitals, Hyder­
abad, India): You said that you performed a renal biopsy in your 
patient initially, and you found a low chronicity index and a very 
high activity index. Why did you not repeat the biopsy, especially 
before transplantation?
D r . B e r d e n : We have one prerequisite for performing a repeat 
biopsy: the results of that biopsy should have therapeutic conse­
quences. If you already are using the most extensive treatment 
protocol, a repeat biopsy is indicated only if you plan to stop the 
treatment if extensive chronic lesions (WHO class VI) are found. 
Our patient did not want to continue extensive immunosuppres­
sive treatment after her fourth renal flare. She accepted the 
eventual development of end-stage renai disease, and hoped for 
successful renal transplantation, as a living kidney donor was 
available. In this instance, a repeat biopsy thus would have had no 
therapeutic consequences.
D r . D imitrios G rekas (Associate Professor o f Nephrology, 
University Hospital Ahepa, Thessaloniki, Greece): Do you continue 
the every-three-month pulse therapy with intravenous cyclophos­
phamide for a finite number of years or indefinitely?
D r . B e r d e n : In the Dutch protocol, it is continued for two 
years in total. We give the cyclophosphamide every month for six 
months, and then administer it every 3 months for 18 months. In 
the NIH protocol, these intravenous cyclophosphamide pulses are 
given for a maximum of 30 months [115]. Because the side effects 
of cyclophosphamide, especially its carcinogenic potential, 
urothelial cell toxicity, and risk of infertility, are related to the 
cumulative dose [108, 112], my advice would be not to exceed a 
treatment period of 30 months.
D r . G rek as: What is your view concerning pregnancy in a 
young woman with SLE nephritis?
D r . B e r d e n : I do not have the time in this Forum to present a 
balanced view on this topic. We would have to take into account 
all the different aspects, such as the effect of pregnancy on SLE, 
the effect of SLE on pregnancy, the impact of the anti-phospho­
lipid syndrome on pregnancy, the neonatal lupus syndrome, and 
the consequences of pregnancy for immunuosuppressive treat­
ment and vice-versa. This discussion by itself could be the subject 
of a Nephrology Forum. So let me offer our general policy, which 
is more or less identical to that for women with other non-lupus 
renal diseases. If the SLE is serologically and clinically inactive, 
the patient has good renal function, a normal blood pressure, and 
no nephrotic-range proteinuria, we do not think that pregnancy is 
contraindicated. But if her disease is active, the serum creatinine 
exceeds 150 /xmol/liter (1.7 mg/dl), or hypertension is present, we 
strongly advise the patient not to become pregnant. Historically, 
physicians have feared that pregnancy or delivery will reactivate 
SLE. But a recent review concluded that the number of patients 
who experienced a disease flare during pregnancy is very low if the 
disease is inactive at conception [188].
D r . M a h e r  R am zy  (Professor o f Renal Medicine, Cairo Univer­
sity, Cairo, Egypt): In your opinion, what is the most sensitive 
serologic marker for disease monitoring, ANA, anti-dsDNA, C3, 
or C4? My second question is: is there a difference in lupus 
between male and female patients?
D r . B e r d e n : Reports from the Netherlands by Swaak et al
[189-192] and by ter Borg and coworkers [6] showed that 80% to 
90% of the disease flares are preceded by a significant rise in 
anti-dsDNA antibodies. These changes were more sensitive than 
were changes in complement profiles. These observations suggest 
that the anti-dsDNA titer is the best parameter for monitoring the 
patient. Of course, changes in C3 and C4 also can be taken into 
account, but these markers are less sensitive. As I said earlier, 
Kallenberg’s group conducted a trial in which treatment was 
guided by changes in anti-dsDNA titers [125]. Another serologic 
marker that could be of potential interest for monitoring lupus 
nephritis is the anti-Clq antibody titer. The sanu group found 
that a rise in anti-Clq preceded a renal flare by 10 weeks [ 
Finally, future research will reveal whether measurement of 
nucleosome-specific autoantibodies will provide a better tool for 
disease monitoring. In view of the pathophysiologic concept that
I presented, this approach seems promising.
Now let me respond to your second question. In a retrospective 
analysis, Miller et al discerned no differences in disease manifes­
tations, disease severity, or positive family history for autoimmune 
diseases when they compared 51 male patients with female lupus 
patients [193]. In a more recent review, Kaufmann and colleagues 
noted a higher incidence of thrombocytopenia and renal disease 
in male lupus patients; all other clinical and serologic parameters 
did not differ [194]. As I already mentioned, the risk of developing 
ESRF is higher in male patients with lupus nephritis than in 
females.
D r . H erm inio  S u a zo  (Nephrologist, Kidney and Hypertension 
Center, Houma, Louisiana, USA): According to the case summary, 
when the patient’s serum creatinine reached 620 /xmol/liter (7.0 
mg/dl), she was started on a low-protein diet. Would you please 
comment on the evidence that dietary protein restriction is 
beneficial in nondiabetic patients with chronic renal disease as 
opposed to the risk of malnutrition in patients starting dialysis?
D r . B e r d e n : The low-protein diet was not prescribed in an 
attempt to influence the progression of her renal disease, but 
because her urea levels were increasing and we wanted to control 
her azotemia. We prescribed 0.8 g of protein/kg body weight, an 
amount that generally does not lead to malnutrition.
D r . M a r ia n o  R o d r ig u e z  (Associate Professor o f Medicine, 
Hospital Universitario Reina Sofia, Cordoba, Spain): Let me return 
to the question of pathogenesis. You mentioned apoptosis as a 
key causative factor in lupus. Has your group or any other group 
demonstrated that peripheral blood mononuclear cells show signs 
of apoptosis in vitro? If this is the case, could these cells be used 
to monitor treatment or detect flares?
D r . B e r d e n : As I mentioned earlier, some observations in the 
literature point to a disturbed apoptosis in lupus. These include an 
increased spontaneous apoptosis in vitro [31, 195], an increased 
expression of Bcl-2 in lymphocytes [42] and, although not uni­
formly confirmed [40, 41], increased circulating levels of soluble 
Fas [39]. Kalden’s group recently reported that phagocytosis of 
apoptotic cells was impaired in lupus patients [196], However, 
none of these parameters has yet been evaluated for its diagnostic 
or prognostic potential. At present, Dr. Smeenk and colleagues 
(CLB, Amsterdam) are performing a prospective study to analyze 
the relation between levels of soluble Fas and disease activity. 
Their preliminary data indicate that disease flares are preceded, 
by as early as 5 months, by an increase of soluble Fas, while in 
patients with inactive disease, the levels remain normal. In the
:
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near future, we will measure the surface expression of phospha- 
tidylserine on peripheral blood lymphocytes, as this is one of the 
first signs of apoptosis at the cell surface. Other cell-surface 
changes that are not yet well-defined [197] also occur on apoptotic 
cells. As soon as these changes are elucidated, their significance 
for SLE can be probed. Finally, since nucleosome release is a key 
feature of apoptosis, measurement of nucleosome auto antibody 
complexes in the circulation of SLE patients could form a new 
tool for monitoring. This approach is now feasible because 
Fotimi6 recently developed a method of measuring these com­
plexes [198].
Dr. Z big niew  H r u b y  (Associate Professor o f Nephrology, Wro­
claw School o f Medicine, Wroclaw): I would like to address the 
issue of flares or relapses that are refractory to treatment. Do you 
think that there is a role for intravenous immunoglobulin for these 
severe cases? Yesterday at this EDTA/ERA Congress Dr. Lock­
wood spoke about the therapeutic potential of intravenous immu­
noglobulin for the management of severe ANCA-associated vas- 
culitides. Today you mentioned anti-GBM auto antibodies that 
could be inhibited by anti-idiotypic antibodies present in these 
immunoglobulin preparations.
D r . B e r d e n : Let me first make sure that my message was clear. 
No anti-GBM antibodies are present in SLE. In our concept, 
autoantibodies are targeted to the GBM, because they are 
complexed in the circulation to nucleosomes, thereby gaining 
affinity for the GBM. I do not have personal experience with 
intravenous immunoglobulin treatment in lupus nephritis. The 
literature contains only a few scattered reports on intravenous 
immunoglobulin therapy in lupus and no controlled data [199, 
200]. In some patients intravenous immunoglobulin therapy had a 
brief but positive effect on extrarenal symptoms. Some patients 
even experienced an exacerbation of glomerulonephritis [199]. I 
do not think that I can recommend this form of treatment on the 
basis of these results.
D r . A id a  R . J. M o u ssa li (Head o f Nephrology Service, Hotel- 
Dieu de France Hospital, Beyrouth, Lebanon): Do you envision a 
role for subcutaneously given heparin in the treatment of lupus, 
based on your experimental animal data?
D r . B e r d e n : In our experimental animal studies, if we started 
early with heparin and non-coagulant heparin derivatives, we 
could prevent proteinuria and could decrease the severity of the 
glomerulonephritis, as assessed by light microscopy and immuno­
fluorescence. However, if we treated animals with already estab­
lished proteinuria and nephritis, we did not observe a reduction in 
proteinuria, although the progression of proteinuria slowed. If we 
added non-coagulant heparin derivatives to a subtherapeutic dose 
of cyclophosphamide, we could prolong survival significantly 
compared to that with cyclosphamide treatment alone [70]. How­
ever, at present no data are available for human lupus. It 
nevertheless remains an intruiging possibility, moreover because 
heparin and heparinoids might have other beneficial effects on 
immune-mediated glomerular pathology, including inhibition of 
mesangial proliferation and sclerosis, modulation of extracellular 
matrix production, inhibition of binding of immune complexes to 
mesangial cells (at least in vitro), inhibition of complement 
activation, and downregulation of T-cell-mediated responses [70].
D r. M o u ssa l i: I have another question regarding the patient 
who was presented. What were the odds of her becoming preg­
nant given the severity of her disease? In my opinion, her disease 
was so severe that the odds for her completing a successful
pregnancy were poor. One more question: did she become 
pregnant after renal transplantation?
D r. B e r d e n : I agree with you that the disease in this patient 
was severe; it led to end-stage renal failure within four years. But 
a lupus patient with this form of nephritis has an 80% chance of 
not developing end-stage renal failure. We were hoping that she 
would respond well to the treatment and that she could become 
pregnant later if she met the criteria I already mentioned in 
response to one of Dr. Grekas’ questions, I agree with you that 
during her disease her chances for a successful pregnancy were 
low, but she rejected cyclophosphamide treatment because of its 
risk of inducing infertility. Your second question was about 
pregnancy after renal transplantation. The patient, now in good 
condition, also raised this question. A search of the literature 
revealed only three lupus patients who received transplants and 
who later became pregnant [201, 202]. Two of the three patients 
carried their pregnancies to term successfully, I think that at the 
moment there are no absolute contraindications for pregnancy in 
our patient.
D r . Ja n  J. W eening  (Professor of Pathology, Department of 
Pathology, Academic Medical Center, University o f Amsterdam, 
Amsterdam, The Netherlands): In your discussion on the mecha­
nisms of induction of SLE, you mentioned the possible role of 
abnormal apoptosis and the appearance of cryptic epitopes, 
Recent studies from Ernst Gleichmann and our own group have 
provided evidence that similar mechanisms might be involved in 
SLE induced by drugs and heavy metals. As you know, a number 
of drugs and heavy metals such as gold and mercuric chloride can 
cause SLE in humans and a lupus-like syndrome in laboratory 
animals. Gleichmann’s group showed that gold can interfere with 
protein folding during antigen processing and result in presenta­
tion of cryptic peptides instead of the usual dominant peptides 
[203], The cryptic peptides are not recognized as self and elicit an 
autoimmune response. In addition, Aten from our group showed 
that mercury can change antigenic peptides in such a way that 
T-cell recognition is altered. Furthermore, Aten showed that 
mercuric chloride can cause apoptosis in lymphocytes and possibly 
lead to immune dysregulation; transfection of the Bcl-2 gene 
resulted in a reduction in mercury-induced apoptosis [204].
D r , B e r d e n : Thank you for this comment, which extends the 
data that I discussed.
D r . R. B anks (Nephrologist, Gloucester Royal Hospital, Glouces­
ter, U.K.): How long would you continue treatment with steroids 
and azathioprine in a stable, quiescent patient? Is it a life-long 
sentence?
D r . B erd en : This is a very important question but one that is 
difficult to answer. To my knowledge, no controlled studies are 
available in which the medication was electively stopped. 
Boumpas et al suggested that quarterly pulses of cyclophospha­
mide should be continued at least one year after remission of 
renal disease is reached [205]. However, these authors did not 
state whether all medication was stopped. In a retrospective 
analysis of 84 SLE patients, Ciruelo and coworkers found that 
after cessation of CPM (given either orally or intravenously), the 
cumulative incidence of relapse of glomerulonephritis was 25% at 
5 years and 46% at 10 years [206]. Risk factors for relapse 
included oral treatment with CPM, onset of nephritis before the 
age of 29 years, and delay of treatment from onset of nephritis for 
more than five months. Similar data are not available for cessation
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of treatment with prednisone and/or azathioprine. In a retrospec­
tive analysis in a relatively small number of patients (n = 25), 
Moroni et al found that after a mean followup of 88 months, II  
patients were stable without treatment. The incidence of lupus 
flare-ups decreased significantly after the tenth year (0,11 flares/ 
patient/year versus 0.31 in the years before) [207]. Until recently, 
we treated our patients with low (alternate-day) doses of pred­
nisone and azathioprine (1.5 mg/kg) for at least 10 years after 
onset of nephritis. In the ongoing Dutch prospective study, 
patients in both treatment arms receive after two years 10 mg of 
prednisone and 2 mg/kg azathioprine, both of which are continued 
for two more years. Thereafter, we taper the medication gradually 
using careful monitoring of clinical and serologic (anti-dsDNA, 
C3, and C4) parameters. The Dutch study will evaluate the 
consequences of this withdrawal policy.
Dr. A lex a n d er  C row e  (Senior Registrar in Nephrology, Royal 
Liveipool University Hospital, Merseyside, U.K.): The patient in the 
presentation received a renal transplant six months after starting 
renal replacement therapy and while her serologic markers were 
negative. What safety criteria do you use for the timing of 
transplantation with respect to lupus?
Dr. B e r d e n : The general policy is to transplant a kidney 6 to 12 
months after the onset of ESRF, in the absence of lupus disease 
activity [127, 208]. However, this policy is based on a prudent 
approach rather than on hard data. No differences were found for 
graft or patient survival between patients who received transplants 
within or after three months of dialysis treatment [209]. Also Goss 
et al reported no clear benefit from a longer dialysis period [137]. 
In the Dutch study on transplantation in lupus patients, disease 
activity prior to transplantation did not influence patient or graft 
survival [135]. It has been suggested, but not unequivocally 
proven, that there is an association between pretransplant positive 
lupus serology and recurrence [137]. Therefore our approach is to 
wait for at least three months to allow for eventual recovery of 
renal function, and to perform transplantation after lupus serol­
ogy has become negative.
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